Caremark Nixes Bid, Avoids Antitrust Scrutiny
Citing antitrust concerns and timing delays, Caremark Rx Inc. has rejected Express Scripts Inc.'s $26 billion offer for the company, preferring to stick with the $21 billion "merger of equals" it...To view the full article, register now.
Already a subscriber? Click here to view full article